Results of a 2-Stage, Phase 3 Pivotal Trial, EDEMA3®: A Study of Subcutaneous DX-88 (Ecallantide), a Plasma Kallikrein Inhibitor, in Patients with Hereditary Angioedema (HAE)

✍ Scribed by LEVY, R; MCNEIL, D; LI, H; HSU, F; HORN, P; ROBERTS, J

• Book ID: 119279821
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 50 KB
• Volume: 121
• Category: Article
• ISSN: 1097-6825
• DOI: 10.1016/j.jaci.2007.12.1190